Ameriprise’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-10,093
| Closed | -$380K | – | 4040 |
|
|
2021
Q1 | $380K | Buy |
+10,093
| New | +$252K | ﹤0.01% | 3505 |
|
|
2020
Q4 | – | Sell |
-54,343
| Closed | -$256K | – | 3871 |
|
|
2020
Q3 | $256K | Buy |
54,343
+2,796
| +5% | +$14.2K | ﹤0.01% | 3469 |
|
|
2020
Q2 | $315K | Buy |
+51,547
| New | +$212K | ﹤0.01% | 3349 |
|
|
2020
Q1 | – | Sell |
-35,094
| Closed | -$161K | – | 3772 |
|
|
2019
Q4 | $161K | Buy |
35,094
+13,964
| +66% | +$55.3K | ﹤0.01% | 3609 |
|
|
2019
Q3 | $82K | Buy |
+21,130
| New | +$116K | ﹤0.01% | 3644 |
|
|
2019
Q2 | – | Sell |
-10,500
| Closed | -$141K | – | 3821 |
|
|
2019
Q1 | $141K | Hold |
10,500
| – | – | ﹤0.01% | 3606 |
|
|
2018
Q4 | $98K | Sell |
10,500
-790
| -7% | -$9.4K | ﹤0.01% | 3533 |
|
|
2018
Q3 | $157K | Buy |
11,290
+700
| +7% | +$10.4K | ﹤0.01% | 3578 |
|
|
2018
Q2 | $167K | Buy |
10,590
+54
| +0.5% | +$942 | ﹤0.01% | 3518 |
|
|
2018
Q1 | $181K | Hold |
10,536
| – | – | ﹤0.01% | 3500 |
|
|
2017
Q4 | $231K | Buy |
+10,536
| New | +$339K | ﹤0.01% | 3428 |
|
|
2014
Q4 | – | Sell |
-5
| Closed | – | – | 4630 |
|
|
2014
Q3 | $0 | Sell |
5
-15
| -75% | -$189 | ﹤0.01% | 5936 |
|
|
2014
Q2 | $0 | Buy |
20
+10
| +100% | +$143 | ﹤0.01% | 5687 |
|
|
2014
Q1 | $0 | Buy |
+10
| New | +$170 | ﹤0.01% | 5432 |
|
Ameriprise's FPRX Position: Q2 2021 in Review
Ameriprise sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 10,093 shares — an estimated $380K sold.
Ameriprise first reported a position in FPRX in Q1 2014 and held it in 14 quarters. The position peaked at $380K in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Ameriprise reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Ameriprise sold 10,093 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $380K.
- Ameriprise first reported a position in Five Prime Therapeutics, Inc. in Q1 2014 and held it in 14 quarters.
- Ameriprise's Five Prime Therapeutics, Inc. position peaked at $380K in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Ameriprise's 13F filing for Q2 2021, filed 16 Aug 2021.